Knopp RH - Search Results

1

Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia.

Knopp RH, Gitter H, Truitt T, Bays H, Manion CV, Lipka LJ, LeBeaut AP, Suresh R, Yang B, Veltri EP; Ezetimibe Study Group. Knopp RH, et al. Eur Heart J. 2003 Apr;24(8):729-41. doi: 10.1016/s0195-668x(02)00807-2. Eur Heart J. 2003. PMID: 12713767 Clinical Trial.

2

Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies.

Bays HE, Moore PB, Drehobl MA, Rosenblatt S, Toth PD, Dujovne CA, Knopp RH, Lipka LJ, Lebeaut AP, Yang B, Mellars LE, Cuffie-Jackson C, Veltri EP; Ezetimibe Study Group. Bays HE, et al. Among authors: knopp rh. Clin Ther. 2001 Aug;23(8):1209-30. doi: 10.1016/s0149-2918(01)80102-8. Clin Ther. 2001. PMID: 11558859 Clinical Trial.

3

Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolaemia: a pooled analysis from two controlled phase III clinical studies.

Knopp RH, Dujovne CA, Le Beaut A, Lipka LJ, Suresh R, Veltri EP; Ezetimbe Study Group. Knopp RH, et al. Int J Clin Pract. 2003 Jun;57(5):363-8. Int J Clin Pract. 2003. PMID: 12846338 Clinical Trial.

4

Lipoprotein effects of combined ezetimibe and colesevelam hydrochloride versus ezetimibe alone in hypercholesterolemic subjects: a pilot study.

Knopp RH, Tsunehara C, Retzlaff BM, Fish B, Nguyen H, Anderson S, Nguyen T. Knopp RH, et al. Metabolism. 2006 Dec;55(12):1697-703. doi: 10.1016/j.metabol.2006.08.013. Metabolism. 2006. PMID: 17142146 Clinical Trial.

5

Effects of pravastatin on apolipoprotein-specific high density lipoprotein subpopulations and low density lipoprotein subclass phenotypes in patients with primary hypercholesterolemia.

Cheung MC, Austin MA, Moulin P, Wolf AC, Cryer D, Knopp RH. Cheung MC, et al. Among authors: knopp rh. Atherosclerosis. 1993 Aug;102(1):107-19. doi: 10.1016/0021-9150(93)90089-d. Atherosclerosis. 1993. PMID: 8257447 Clinical Trial.

6

Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia.

Broyles FE, Walden CE, Hunninghake DB, Hill-Williams D, Knopp RH. Broyles FE, et al. Among authors: knopp rh. Am J Cardiol. 1995 Jul 13;76(2):129A-135A. doi: 10.1016/s0002-9149(05)80035-9. Am J Cardiol. 1995. PMID: 7604788 Clinical Trial.

7

Long-term blood cholesterol-lowering effects of a dietary fiber supplement.

Knopp RH, Superko HR, Davidson M, Insull W, Dujovne CA, Kwiterovich PO, Zavoral JH, Graham K, O'Connor RR, Edelman DA. Knopp RH, et al. Am J Prev Med. 1999 Jul;17(1):18-23. doi: 10.1016/s0749-3797(99)00039-2. Am J Prev Med. 1999. PMID: 10429748 Clinical Trial.

8

Effect of fenofibrate treatment on plasma lipoprotein lipids, high-density lipoprotein cholesterol subfractions, and apolipoproteins B, AI, AII, and E.

Knopp RH, Walden CE, Warnick GR, Albers JJ, Ginsberg J, McGinnis BM. Knopp RH, et al. Am J Med. 1987 Nov 27;83(5B):75-84. doi: 10.1016/0002-9343(87)90875-8. Am J Med. 1987. PMID: 3120587 Clinical Trial.

9

Effects of fenofibrate on plasma lipoproteins in hypercholesterolemia and combined hyperlipidemia.

Knopp RH, Brown WV, Dujovne CA, Farquhar JW, Feldman EB, Goldberg AC, Grundy SM, Lasser NL, Mellies MJ, Palmer RH, et al. Knopp RH, et al. Am J Med. 1987 Nov 27;83(5B):50-9. doi: 10.1016/0002-9343(87)90871-0. Am J Med. 1987. PMID: 3318454 Clinical Trial.

10

Management of patients with diabetic hyperlipidemia.

Knopp RH, Retzlaff B, Aikawa K, Kahn SE. Knopp RH, et al. Am J Cardiol. 2003 Apr 3;91(7A):24E-28E. doi: 10.1016/s0002-9149(02)03385-4. Am J Cardiol. 2003. PMID: 12679200 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

270 results

Search Page

Filters